NK-92MI

NK-92MI

收藏
  • 询价
  • 2025年12月20日
    avatar
    14金牌会员
  • 企业认证

  • 万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 询价记录
    • 技术资料
    • 物种来源

    • 是否是肿瘤细胞

      1

    • 细胞类型

      其他细胞类型

    • 细胞形态

      淋巴样

    • 库存

      大量

    • 年限

      50 years

    • 运输方式

      冻存运输

    • 生长状态

      悬浮生长,多细胞聚集

    • 相关疾病

      其他疾病

    • ATCC Number

      CRL-2408™

    Designations: NK-92MI
    Depositors:  Conkwest Inc.
    Biosafety Level: 2
    Shipped: frozen
    Medium & Serum: See Propagation
    Growth Properties: suspension, multicell aggregates
    Organism: Homo sapiens deposited as human
    Morphology: lymphoblast

    Source: Disease: malignant non-Hodgkin's lymphoma
    Cell Type: natural killer cell; NK cell;
    Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
    DNA Profile (STR): D5S818: 12. 13
    D13S317: 9, 12
    D7S820: 10, 11
    D16S539: 11, 12
    vWA: 16, 18
    THO1: 6, 9.3
    TPOX: 8
    CSF1PO: 11, 12
    Amelogenin: X, Y
    Age: 50 years
    Gender: male
    Ethnicity: Caucasian
    Comments: NK-92 is an interleukin-2 (IL-2) dependent Natural Killer Cell line derived from peripheral blood mononuclear cells from a 50 year old Caucasian male with rapidly progressive non-Hodgkin's lymphoma. NK-92MI is an interleukin-2 (IL-2) independent Natural Killer Cell line derived from the NK-92 (ATCC CRL-2407 ) cell line by transfection. The parental cells were transfected with human IL-2 cDNA in the retroviral MFG-hIL-2 vector by particle-mediated gene transfer. The transfection is stable, most likely due to integration of the vector into genomic DNA. The cell line is cytotoxic to a wide range of malignant cells; it kills both K562 cells and Daudi cells in chromium release assays. NK-92 and derivative cell line NK-92MI have the following characteristics: surface marker positive for CD2, CD7, CD11a, CD28, CD45, CD54 and CD56 bright; surface marker negative for CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34 and HLA-DR. The parental IL-2 dependent cell line is available as CRL-2407 (NK-92). NK-92MI was shown to contain, express, and synthesize the hIL-2. A culture submitted to the ATCC in September of 1998 was found to be contaminated with mycoplasma. Progeny were cured by a 21-day treatment with BM Cycline. The cells were assayed for mycoplasma, by the Hoechst stain, PCR and the standard culture test, after a six-week period following treatment. All tests were negative.
    Propagation: ATCC complete growth medium: The base medium for this cell line is Alpha Minimum Essential medium without ribonucleosides and deoxyribonucleosides but with 2 mM L-glutamine and 1.5 g/L sodium bicarbonate . To make the complete growth medium, add the following components to the base medium: 0.2 mM inositol; 0.1 mM 2-mercaptoethanol; 0.02 mM folic acid; horse serum to a final concentration of 12.5%; fetal bovine serum to a final concentration of 12.5%.
    Temperature: 37.0°C
    Atmosphere: air, 95%; carbon dioxide (CO2), 5%
    Subculturing: Protocol: Cultures can be maintained by centrifuging cells and resuspending cell pellet in fresh medium at 2 - 3 X 105 viable cells/mL. Centrifugation and full replacement of culture medium may be performed for the first subcultures. Cultures can then be maintained by addition of fresh medium. Pipet the cells up and down on the back of the flask every 2-3 days to produce a single cell suspension. Maintain cell density between 2 X 10 5 and 1 X 10 6 viable cells/ml or use a 1:3 spilt ratio.
    Preservation: Freeze medium: FBS, 90%; DMSO, 10%
    Storage temperature: liquid nitrogen vapor phase
    Related Products: recommended serum: ATCC 30-2020
    recommended serum: ATCC 30-2040
    parental cell line: ATCC CRL-2407 (EBV po
    References: 38894: Gong JH, et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260
    38969: Tam YK, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666
    40184: Tam YK, et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999. PubMed: 10417052

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    • 作者
    • 内容
    • 询问日期
    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥1800
    博辉生物科技(广州)有限公司
    2025年11月20日询价
    ¥2800
    上海酶研生物科技有限公司
    2025年07月11日询价
    ¥680
    上海联迈生物工程有限公司
    2025年08月14日询价
    ¥2200
    上海钰博生物科技有限公司
    2025年07月13日询价
    询价
    ATCC细胞库
    2025年12月25日询价
    NK-92MI
    询价